Keros Therapeutics, Inc. Company Information

Keros Therapeutics, Inc.'s employee growth, exchange listings and data sources

Key Information

Name: Keros Therapeutics, Inc.
Ticker: KROS
Exchange: NasdaqGM
Founded: 2015
Industry: Biotechnology
Sector: Pharmaceuticals & Biotech
Market Cap: US$665.132m
Shares Outstanding: 40.51m
Website: https://www.kerostx.com

Number of Employees

Location

Keros Therapeutics, Inc.
1050 Waltham Street
Suite 302
Lexington
Massachusetts
02421
United States

Listings

Ticker	Exchange	Primary Security	Security Type	Country	Currency	Listed on
KROS	NasdaqGM (Nasdaq Global Market)	Yes	Common Stock	US	USD	Apr 2020

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
Data	Last Updated (UTC time)
Company Analysis	2024/12/30 07:48
End of Day Share Price	2024/12/30 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/30 07:48
End of Day Share Price	2024/12/30 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Keros Therapeutics, Inc. is covered by 19 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Gregory Harrison	BofA Global Research
Jason Zemansky	BofA Global Research
Prakhar Agrawal	Cantor Fitzgerald & Co.